Integra LifeSciences Shares Surge On Q3 Beat

Integra LifeSciences Holdings Corp IART reported Q3 FY22 sales of $385.19 million, -0.4% Y/Y on a reported basis, and +3.5% organic, beating the consensus of $381.24 million.
Adjusted EPS stood at $0.86, ahead of the Street estimate of $0.73.
Adjusted gross margin was 66.7%, compared to 68.3% in the prior year.
Adjusted EBITDA was $105.3 million, or 27.3% of revenue, compared to $104.3 million, or 27.0% of revenue, in the prior year.
The company completed the sale of its non-core traditional wound care business at the end of August 2022.
Guidance: For FY22, Integra Lifescience sees revenue of $1.551-$1.563 billion (prior view $1.548-$1.566 billion).
The guidance considers the macro environment, continuing supply constraints, and potential adjustments to the CereLink reserve.
The company raised FY22 adjusted EPS to $3.29-$3.33 vs. the earlier outlook of $3.12-$3.20 and the consensus of $3.15.
For Q4, IART expects sales of $391-$403 million vs. the consensus of $403.5 million. It sees adjusted EPS of $0.87-$0.91 (consensus of $0.88).
Price Action: IART shares are up 5.43% at $47.02 on the last check Wednesday.